Azure Farm

Azure Biotech is a clinical-stage biotechnology company focused on developing repurposed and reformulated therapies for women's health. The company's lead program is a reformulated version of lasofoxifene, a selective estrogen receptor modulator (SERM) licensed from Ligand Pharmaceuticals, which is being developed for the treatment of vulvovaginal atrophy (VVA) in postmenopausal women. Azure Biotech aims to provide non-estrogen alternatives for serious menopausal conditions, particularly for breast cancer survivors who cannot use traditional hormone replacement therapies. The company is led by a team with extensive experience in pharmaceutical research and development from major firms such as Pfizer and Novartis.